PL2316431T3 - Kompozycja w postaci stałego preparatu do stosowania doustnego obejmująca agonistę receptora S1P i alkohol cukrowy - Google Patents

Kompozycja w postaci stałego preparatu do stosowania doustnego obejmująca agonistę receptora S1P i alkohol cukrowy

Info

Publication number: PL2316431T3
Authority: PL; Poland
Prior art keywords: receptor agonist; sugar alcohol; oral composition; solid oral; solid
Prior art date: 2003-04-08

Application number

PL10184951.1T

Other languages

English (en)

Inventor

Tomoyuki Oomura

Madhusudhan Pudipeddi

Alan Edward Royce

Colleen Ruegger

Masaki Sasaki

Tokuhiro Tamura

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-08

Filing date

2004-04-06

Publication date

2016-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2316431(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-04-06 Application filed filed Critical

2016-09-30 Publication of PL2316431T3 publication Critical patent/PL2316431T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biochemistry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Surgery (AREA)
Rheumatology (AREA)
Virology (AREA)
Psychiatry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

PL10184951.1T 2003-04-08 2004-04-06 Kompozycja w postaci stałego preparatu do stosowania doustnego obejmująca agonistę receptora S1P i alkohol cukrowy PL2316431T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US46121503P	2003-04-08	2003-04-08

Publications (1)

Publication Number	Publication Date
PL2316431T3 true PL2316431T3 (pl)	2016-09-30

Family

ID=32326722

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL10184951.1T PL2316431T3 (pl)	2003-04-08	2004-04-06	Kompozycja w postaci stałego preparatu do stosowania doustnego obejmująca agonistę receptora S1P i alkohol cukrowy
PL04725895T PL1613288T3 (pl)	2003-04-08	2004-04-06	Stała kompozycja farmaceutyczna zawierająca agonistę receptora S1P oraz alkohol cukrowy

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL04725895T PL1613288T3 (pl)	2003-04-08	2004-04-06	Stała kompozycja farmaceutyczna zawierająca agonistę receptora S1P oraz alkohol cukrowy

Country Status (42)

Country	Link
US (11)	US20060275357A1 (pl)
EP (5)	EP2316431B1 (pl)
JP (3)	JP5495467B2 (pl)
KR (3)	KR20050121712A (pl)
CN (2)	CN101797241B (pl)
AR (3)	AR043987A1 (pl)
AT (3)	ATE414508T1 (pl)
AU (1)	AU2004228929B2 (pl)
BE (2)	BE1015972A5 (pl)
BR (1)	BRPI0409250B8 (pl)
CA (2)	CA2521325C (pl)
CL (2)	CL2004000745A1 (pl)
CY (3)	CY1110260T1 (pl)
DE (4)	DE202004021680U1 (pl)
DK (2)	DK2316431T3 (pl)
EC (1)	ECSP056090A (pl)
ES (3)	ES2556947T3 (pl)
FR (2)	FR2854073B1 (pl)
GB (1)	GB2400318B (pl)
GR (1)	GR1005052B (pl)
HK (3)	HK1071685A1 (pl)
HR (3)	HRP20050886B1 (pl)
HU (2)	HUE028247T2 (pl)
IL (3)	IL170888A (pl)
IS (2)	IS2682B (pl)
IT (1)	ITMI20040682A1 (pl)
LU (1)	LU91867I2 (pl)
MA (1)	MA27729A1 (pl)
MX (1)	MXPA05010860A (pl)
MY (1)	MY141249A (pl)
NO (4)	NO329332B1 (pl)
NZ (3)	NZ586280A (pl)
PE (5)	PE20130200A1 (pl)
PL (2)	PL2316431T3 (pl)
PT (1)	PT1613288E (pl)
RU (5)	RU2358716C2 (pl)
SG (1)	SG175449A1 (pl)
SI (2)	SI1613288T1 (pl)
TN (1)	TNSN05256A1 (pl)
TW (1)	TWI332847B (pl)
WO (1)	WO2004089341A1 (pl)
ZA (1)	ZA200507394B (pl)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1773307B8 (en) *	2004-07-30	2014-12-17	Novartis AG	Compound formulations of 2-amino-1,3-propanediol compounds
CN1891212B (zh) *	2005-07-07	2010-10-13	马启明	一种口服制剂及其制备方法
ES2529724T3 (es) *	2005-09-09	2015-02-25	Novartis Ag	Tratamiento de enfermedades autoinmunes
KR101274417B1 (ko)	2005-11-09	2013-06-17	프로테올릭스, 인코퍼레이티드	효소 저해를 위한 화합물
TWI389683B (zh) *	2006-02-06	2013-03-21	Kyorin Seiyaku Kk	A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
NZ597545A (en)	2006-06-19	2013-07-26	Proteolix Inc	Peptide epoxyketones for proteasome inhibition
GB0612721D0 (en)	2006-06-27	2006-08-09	Novartis Ag	Organic compounds
WO2008037421A2 (en) *	2006-09-26	2008-04-03	Novartis Ag	Pharmaceutical compositions comprising an s1p modulator
EP1923054A1 (en) *	2006-09-26	2008-05-21	Novartis AG	Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1923055A1 (en) *	2006-09-26	2008-05-21	Novartis AG	Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
EP1923058A1 (en) *	2006-09-26	2008-05-21	Novartis AG	Coated pharmaceutical composition comprising an S1P agonist or modulator
EP1905434A1 (en) *	2006-09-26	2008-04-02	Novartis AG	Organic compounds comprising an S1P receptor agonist and their therapeutic use
AU2011235934A1 (en) *	2006-09-26	2011-11-03	Novartis Ag	Pharmaceutical compositions comprising an S1P modulator
WO2008124210A1 (en) *	2007-02-14	2008-10-16	Emory University	Methods and compositions for treating or preventing infection using leukocyte sequestration agents
CN104324015B (zh) *	2007-03-29	2018-08-28	第一三共株式会社	药物组合物
HUE029665T2 (en)	2007-10-04	2017-03-28	Onyx Therapeutics Inc	Synthesis of crystalline peptide epoxy ketone protease inhibitors and amino acid keto epoxides \ t
SI2952177T1 (sl) *	2007-10-12	2021-07-30	Novartis Ag	Sestavki, ki vsebujejo modulatorje receptorja sfingozin 1 fosfata (s1p)
AU2012216630B2 (en) *	2007-10-12	2015-01-22	Novartis Ag	Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP5534645B2 (ja) *	2008-01-11	2014-07-02	日医工株式会社	無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
JP5452237B2 (ja)	2008-02-07	2014-03-26	杏林製薬株式会社	アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
BRPI0909625B1 (pt)	2008-03-17	2021-09-08	Actelion Pharmaceuticals Ltd	Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1
EP3545953A1 (en)	2008-06-20	2019-10-02	Novartis AG	Paediatric compositions for treating1 multiple sclerosis
ES2676288T3 (es) *	2008-06-20	2018-07-18	Merck Patent Gmbh	Matriz de comprimidos directamente compresible y rápidamente desintegrable
EP2334202B1 (en) *	2008-09-04	2012-02-01	Cargill, Incorporated	Tabletting of ervthritol
EP2349313A4 (en)	2008-10-21	2012-08-29	Onyx Therapeutics Inc	COMBINATION THERAPY WITH EPOXYCLETON PEPTIDES
WO2010055027A2 (en)	2008-11-11	2010-05-20	Novartis Ag	Organic compounds
CA2743232C (en) *	2008-11-11	2015-12-29	Novartis Ag	Crystalline forms of fingolimod hcl
AU2013100532B4 (en) *	2008-11-11	2013-11-28	Novartis Ag	Crystalline forms of fingolimod HCL
EP2371830B1 (en)	2008-12-17	2013-10-02	Daiichi Sankyo Company, Limited	Method for producing diamine derivative
JPWO2010082531A1 (ja)	2009-01-13	2012-07-05	第一三共株式会社	活性化血液凝固因子阻害剤
JP5666424B2 (ja)	2009-03-10	2015-02-12	第一三共株式会社	ジアミン誘導体の製造方法
EP2407450B1 (en)	2009-03-13	2015-04-22	Daiichi Sankyo Company, Limited	Method for producing optically active diamine derivative
AR075899A1 (es)	2009-03-20	2011-05-04	Onyx Therapeutics Inc	Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
CN102481296A (zh) *	2009-06-18	2012-05-30	第一三共株式会社	溶解性改善的药用组合物
US9675566B2 (en)	2009-07-16	2017-06-13	Pathologica Llc	Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
EP2498793B1 (en)	2009-11-13	2019-07-10	Onyx Therapeutics, Inc.	Oprozomib for use in metastasis suppression
KR20130075723A (ko)	2010-03-01	2013-07-05	오닉스 세라퓨틱스, 인크.	면역프로테아좀 저해를 위한 화합물
WO2011115066A1 (ja)	2010-03-19	2011-09-22	第一三共株式会社	ジアミン誘導体の結晶およびその製造方法
BR112012023654B1 (pt)	2010-03-19	2022-04-12	Daiichi Sankyo Company, Limited	Método para produzir grânulos contendo agente anticoagulante e método para produzir uma composição farmacêutica contendo o dito agente
US20130095177A1 (en) *	2010-04-22	2013-04-18	Ratiopharm Gmbh	Method of preparing an oral dosage form comprising fingolimod
CN103080078B (zh)	2010-07-02	2015-02-11	第一三共株式会社	光学活性二胺衍生物盐的制备方法
US9266816B2 (en)	2010-11-25	2016-02-23	Shilpa Medicare Limited	Fingolimod polymorphs and their processes
PT2661261T (pt)	2011-01-07	2019-10-25	Novartis Ag	Formulações imunossupressoras.
PL2665471T3 (pl)	2011-01-19	2018-06-29	Pathologica, Llc.	Doustne farmaceutyczne postacie dawkowane o kontrolowanym uwalnianiu zawierające mgbg
AR085749A1 (es)	2011-04-01	2013-10-23	Novartis Ag	Formulaciones
EA028950B1 (ru)	2011-08-01	2018-01-31	Тева Фармасьютикал Индастриз Лтд.	Способ получения фармацевтических композиций, содержащих финголимод
CA2844604C (en)	2011-08-10	2017-07-18	Daiichi Sankyo Company, Limited	Pharmaceutical composition containing ethanediamide derivatives
WO2013091704A1 (en)	2011-12-22	2013-06-27	Synthon Bv	Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) *	2012-04-26	2013-05-27	Открытое акционерное общество "Новосибхимфарм"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) *	2012-06-13	2014-02-20	Открытое акционерное общество "Новосибхимфарм"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2014011695A2 (en)	2012-07-09	2014-01-16	Onyx Therapeutics, Inc.	Prodrugs of peptide epoxy ketone protease inhibitors
RU2496486C1 (ru) *	2012-07-11	2013-10-27	Александр Васильевич Иващенко	Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
CA2896977C (en)	2013-01-08	2021-12-07	Pathologica Llc	Methods and compositions for treatment of demyelinating diseases
WO2014141298A2 (en) *	2013-03-11	2014-09-18	Astron Research Limited	Stable pharmaceutical composition of fingolimod
ES2733920T3 (es) *	2013-04-26	2019-12-03	Univ Kyoto	Composición que comprende un agonista del receptor 1 de esfingosina-1-fosfato para inhibir la formación y/o el aumento de tamaño de un aneurisma cerebral o para reducirlo
WO2013190151A1 (en) *	2013-05-13	2013-12-27	Synthon B.V.	Pharmaceutical composition comprising fingolimod
JP6316422B2 (ja) *	2013-07-29	2018-04-25	アイザントドラッグリサーチソリューションズプライベートリミテッドＡｉｚａｎｔＤｒｕｇＲｅｓｅａｒｃｈＳｏｌｕｔｉｏｎｓＰｖｔＬｔｄ	フィンゴリモドの医薬組成物
RU2530626C1 (ru) *	2013-10-21	2014-10-10	Ооо "Валента-Интеллект"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2016026461A1 (en) *	2014-08-22	2016-02-25	Sunshine Lake Pharma Co., Ltd.	Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) *	2014-09-19	2016-03-24	Aizant Drug Research Pvt. Ltd	Pharmaceutical compositions of fingolimod
WO2016118515A1 (en) *	2015-01-20	2016-07-28	Handa Pharmaceuticals, Llc	Stable solid fingolimod dosage forms
US9925138B2 (en)	2015-01-20	2018-03-27	Handa Pharmaceuticals, Llc	Stable solid fingolimod dosage forms
WO2016135644A1 (en)	2015-02-26	2016-09-01	Novartis Ag	Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) *	2015-04-09	2016-03-10	Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус"	Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) *	2015-05-28	2017-06-27	Axogen Corporation	Quantitative structural assay of a nerve graft
US11434200B2 (en)	2017-03-09	2022-09-06	Novartis Ag	Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3419607B1 (en)	2017-03-29	2019-11-20	Deva Holding Anonim Sirketi	Stable formulations of fingolimod
GR1009654B (el)	2018-08-31	2019-11-18	Φαρματεν Α.Β.Ε.Ε.	Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de)	2018-10-10	2020-04-16	Harbins Ruhr Bioscience, Inc.	Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) *	2020-05-18	2024-06-20	東和薬品株式会社	フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
EP4181906A1 (en)	2020-07-16	2023-05-24	Harbins Ruhr Bioscience, Inc.	Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL7607683A (nl) *	1976-07-12	1978-01-16	Akzo Nv	Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) *	1977-05-05	1978-08-29	Chevron Research Company	1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en)	1983-10-25	1985-12-17	Phillips Petroleum Company	Metal working lubricant
US5112616A (en) *	1988-11-30	1992-05-12	Schering Corporation	Fast dissolving buccal tablet
JP2841857B2 (ja) *	1990-11-29	1998-12-24	田辺製薬株式会社	長期間安定な経口用医薬製剤
ES2126658T3 (es)	1992-10-21	1999-04-01	Yoshitomi Pharmaceutical	Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
KR100358922B1 (ko)	1994-08-22	2003-01-24	미쯔비시 웰 파마 가부시키가이샤	벤젠화합물및그의의약으로서의용도
CA2213989C (en)	1995-12-28	2007-05-29	Yoshitomi Pharmaceutical Industries Ltd.	External preparation for topical administration
US6476004B1 (en) *	1996-07-18	2002-11-05	Mitsubishi Pharma Corporation	Pharmaceutical composition
JPH11209277A (ja) *	1998-01-19	1999-08-03	Yoshitomi Pharmaceut Ind Ltd	医薬組成物
JP2002241272A (ja)	1996-07-18	2002-08-28	Mitsubishi Pharma Corp	医薬処方組成物
GB9624038D0 (en)	1996-11-19	1997-01-08	Sandoz Ltd	Organic compounds
RU2188004C2 (ru) *	1997-02-27	2002-08-27	Велфайд Корпорейшн	Фармацевтическая композиция
US6214873B1 (en) *	1997-04-04	2001-04-10	Welfide Corporation	2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
JPH1180026A (ja)	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja)	1998-04-01	2004-07-21	花王株式会社	スフィンゴ糖脂質の製造法
JP4627356B2 (ja)	1999-06-30	2011-02-09	松森　　昭	ウイルス性心筋炎の予防または治療薬剤
EP1195165A4 (en) *	1999-07-12	2005-08-10	Ono Pharmaceutical Co	FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS
PL359411A1 (pl)	2000-07-13	2004-08-23	Sankyo Company, Limited	Pochodne aminoalkoholowe
AU2001285331B2 (en)	2000-08-31	2006-04-06	Merck & Co., Inc.	Phosphate derivatives as immunoregulatory agents
US6953332B1 (en)	2000-11-28	2005-10-11	St. Jude Medical, Inc.	Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
DE60208355T2 (de)	2001-03-26	2006-07-27	Novartis Ag	2-amino-propanol derivate
US7521192B2 (en) *	2001-04-18	2009-04-21	Rigel Pharmaceuticals, Inc.	EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja)	2001-04-20	2002-10-31	Sankyo Co Ltd	ベンゾチオフェン誘導体
US20040235794A1 (en)	2001-09-04	2004-11-25	Shinji Nakade	Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
WO2003029205A1 (fr)	2001-09-27	2003-04-10	Kyorin Pharmaceutical Co., Ltd.	Derive de sulfure de diaryle, son sel d'addition et immunosuppresseur
JP4152884B2 (ja)	2001-09-27	2008-09-17	杏林製薬株式会社	ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
EP1470137B1 (en)	2002-01-18	2009-09-02	Merck & Co., Inc.	Edg receptor agonists
JP2005519915A (ja)	2002-01-18	2005-07-07	セレテック・リミテッド・ライアビリティ・カンパニー	Ｅｄｇ受容体に関連する症状の処置方法
WO2003061567A2 (en)	2002-01-18	2003-07-31	Merck & Co., Inc.	Selective s1p1/edg1 receptor agonists
ATE448193T1 (de)	2002-01-18	2009-11-15	Merck & Co Inc	ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
JP4917433B2 (ja) *	2004-07-16	2012-04-18	杏林製薬株式会社	効果的な医薬の使用法及び副作用発現の防御に関する方法

2004
- 2004-04-06 WO PCT/EP2004/003656 patent/WO2004089341A1/en active Application Filing
- 2004-04-06 SI SI200431037T patent/SI1613288T1/sl unknown
- 2004-04-06 NZ NZ586280A patent/NZ586280A/en not_active IP Right Cessation
- 2004-04-06 PE PE2012002027A patent/PE20130200A1/es not_active Application Discontinuation
- 2004-04-06 NZ NZ542622A patent/NZ542622A/xx not_active IP Right Cessation
- 2004-04-06 JP JP2004111761A patent/JP5495467B2/ja not_active Expired - Lifetime
- 2004-04-06 AT AT04725895T patent/ATE414508T1/de active
- 2004-04-06 CN CN2010101213007A patent/CN101797241B/zh not_active Expired - Lifetime
- 2004-04-06 KR KR1020057019066A patent/KR20050121712A/ko not_active Application Discontinuation
- 2004-04-06 US US10/552,005 patent/US20060275357A1/en not_active Abandoned
- 2004-04-06 EP EP10184951.1A patent/EP2316431B1/en not_active Revoked
- 2004-04-06 RU RU2005134173/15A patent/RU2358716C2/ru not_active IP Right Cessation
- 2004-04-06 EP EP14163450.1A patent/EP2769713A1/en not_active Withdrawn
- 2004-04-06 BR BRPI0409250A patent/BRPI0409250B8/pt active IP Right Grant
- 2004-04-06 CA CA2521325A patent/CA2521325C/en not_active Expired - Lifetime
- 2004-04-06 PT PT04725895T patent/PT1613288E/pt unknown
- 2004-04-06 PE PE2004000355A patent/PE20050396A1/es not_active Application Discontinuation
- 2004-04-06 SI SI200432283T patent/SI2316431T1/sl unknown
- 2004-04-06 NZ NZ592339A patent/NZ592339A/xx not_active IP Right Cessation
- 2004-04-06 ES ES10184951.1T patent/ES2556947T3/es not_active Expired - Lifetime
- 2004-04-06 PE PE2008001684A patent/PE20090743A1/es not_active Application Discontinuation
- 2004-04-06 AU AU2004228929A patent/AU2004228929B2/en active Active
- 2004-04-06 PE PE2015000303A patent/PE20150676A1/es not_active Application Discontinuation
- 2004-04-06 KR KR1020107029859A patent/KR20110005320A/ko not_active Application Discontinuation
- 2004-04-06 CN CN2004800092370A patent/CN1767819B/zh not_active Expired - Lifetime
- 2004-04-06 ES ES200400852A patent/ES2228282B1/es not_active Expired - Fee Related
- 2004-04-06 DK DK10184951.1T patent/DK2316431T3/en active
- 2004-04-06 EP EP10186307A patent/EP2319502A1/en not_active Withdrawn
- 2004-04-06 ES ES04725895T patent/ES2320767T3/es not_active Expired - Lifetime
- 2004-04-06 GR GR20040100121A patent/GR1005052B/el unknown
- 2004-04-06 PL PL10184951.1T patent/PL2316431T3/pl unknown
- 2004-04-06 MX MXPA05010860A patent/MXPA05010860A/es active IP Right Grant
- 2004-04-06 SG SG2008040545A patent/SG175449A1/en unknown
- 2004-04-06 FR FR0450692A patent/FR2854073B1/fr not_active Expired - Lifetime
- 2004-04-06 HU HUE10184951A patent/HUE028247T2/en unknown
- 2004-04-06 PL PL04725895T patent/PL1613288T3/pl unknown
- 2004-04-06 DE DE202004021680U patent/DE202004021680U1/de not_active Expired - Lifetime
- 2004-04-06 EP EP08161161A patent/EP2008650A3/en not_active Withdrawn
- 2004-04-06 KR KR1020127019448A patent/KR101367574B1/ko active IP Right Grant
- 2004-04-06 DE DE102004016947A patent/DE102004016947A1/de active Pending
- 2004-04-06 DE DE201112100047 patent/DE122011100047I1/de active Pending
- 2004-04-06 AR ARP040101162A patent/AR043987A1/es not_active Application Discontinuation
- 2004-04-06 GB GB0407819A patent/GB2400318B/en not_active Expired - Lifetime
- 2004-04-06 IT IT000682A patent/ITMI20040682A1/it unknown
- 2004-04-06 PE PE2013000382A patent/PE20131352A1/es active IP Right Grant
- 2004-04-06 DE DE602004017847T patent/DE602004017847D1/de not_active Expired - Lifetime
- 2004-04-06 DK DK04725895T patent/DK1613288T3/da active
- 2004-04-06 EP EP04725895A patent/EP1613288B1/en not_active Expired - Lifetime
- 2004-04-06 AT ATA606/2004A patent/AT501681B1/de not_active IP Right Cessation
- 2004-04-06 CA CA2707750A patent/CA2707750A1/en not_active Abandoned
- 2004-04-07 TW TW093109631A patent/TWI332847B/zh active
- 2004-04-07 MY MYPI20041275A patent/MY141249A/en unknown
- 2004-04-07 BE BE2004/0180A patent/BE1015972A5/fr not_active IP Right Cessation
- 2004-04-07 CL CL200400745A patent/CL2004000745A1/es unknown
2005
- 2005-03-31 HK HK05102715A patent/HK1071685A1/xx not_active IP Right Cessation
- 2005-09-14 ZA ZA200507394A patent/ZA200507394B/en unknown
- 2005-09-15 IL IL170888A patent/IL170888A/en active IP Right Grant
- 2005-10-06 HR HR20050886A patent/HRP20050886B1/xx not_active IP Right Cessation
- 2005-10-07 EC EC2005006090A patent/ECSP056090A/es unknown
- 2005-10-07 TN TNP2005000256A patent/TNSN05256A1/en unknown
- 2005-10-19 MA MA28560A patent/MA27729A1/fr unknown
- 2005-11-01 IS IS8114A patent/IS2682B/is unknown
- 2005-11-07 NO NO20055231A patent/NO329332B1/no active Protection Beyond IP Right Term
2006
- 2006-07-06 HK HK06107621.6A patent/HK1091114A1/xx not_active IP Right Cessation
2008
- 2008-05-08 AT AT0074408A patent/AT504853A2/de not_active Application Discontinuation
- 2008-08-11 US US12/189,323 patent/US8324283B2/en not_active Expired - Fee Related
- 2008-08-13 US US12/191,098 patent/US20090203798A1/en not_active Abandoned
2009
- 2009-02-17 RU RU2009105403/15A patent/RU2009105403A/ru not_active Application Discontinuation
- 2009-02-19 CY CY20091100192T patent/CY1110260T1/el unknown
- 2009-03-12 IL IL197578A patent/IL197578A/en active IP Right Grant
2010
- 2010-02-18 NO NO20100250A patent/NO334116B1/no unknown
- 2010-02-25 IS IS8885A patent/IS8885A/is unknown
- 2010-08-25 JP JP2010188835A patent/JP5543298B2/ja not_active Expired - Lifetime
- 2010-10-26 AR ARP100103930A patent/AR078781A2/es not_active Application Discontinuation
- 2010-10-26 AR ARP100103931A patent/AR078782A2/es not_active Application Discontinuation
- 2010-11-08 HR HR20100600A patent/HRP20100600A2/hr not_active Application Discontinuation
- 2010-11-08 HR HRP20100601AA patent/HRP20100601B1/hr not_active IP Right Cessation
- 2010-11-17 RU RU2010146697/15A patent/RU2475236C2/ru active
- 2010-11-18 RU RU2010147000/15A patent/RU2475237C2/ru active
2011
- 2011-01-10 US US12/987,726 patent/US20110105620A1/en not_active Abandoned
- 2011-03-01 CL CL2011000450A patent/CL2011000450A1/es unknown
- 2011-09-06 HU HUS1100016C patent/HUS1100016I1/hu unknown
- 2011-09-08 LU LU91867C patent/LU91867I2/fr unknown
- 2011-09-08 CY CY2011013C patent/CY2011013I1/el unknown
- 2011-09-08 NO NO2011016C patent/NO2011016I2/no unknown
- 2011-09-08 FR FR11C0036C patent/FR11C0036I2/fr active Active
- 2011-09-08 BE BE2011C030C patent/BE2011C030I2/fr unknown
- 2011-09-21 HK HK11109933.8A patent/HK1155647A1/xx not_active IP Right Cessation
2012
- 2012-11-15 RU RU2012148593/15A patent/RU2012148593A/ru not_active Application Discontinuation
- 2012-12-20 US US13/721,278 patent/US20130108675A1/en not_active Abandoned
2013
- 2013-04-23 JP JP2013090602A patent/JP2013177404A/ja active Pending
- 2013-09-16 US US14/027,943 patent/US20140011885A1/en not_active Abandoned
- 2013-09-26 NO NO20131287A patent/NO335120B1/no unknown
2014
- 2014-05-23 US US14/285,808 patent/US20140255497A1/en not_active Abandoned
2015
- 2015-10-12 IL IL242037A patent/IL242037A0/en unknown
- 2015-12-29 CY CY20151101194T patent/CY1117071T1/el unknown
2017
- 2017-06-27 US US15/634,579 patent/US20170290787A1/en not_active Abandoned
2019
- 2019-02-13 US US16/274,357 patent/US20190175527A1/en not_active Abandoned
2020
- 2020-04-03 US US16/839,703 patent/US20200237690A1/en not_active Abandoned
2021
- 2021-10-14 US US17/501,173 patent/US20220031609A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2556947T3 (es)	2016-01-21
ITMI20040682A1 (it)	2004-07-06
NZ586280A (en)	2011-12-22
GB2400318B (en)	2005-08-10
US20140011885A1 (en)	2014-01-09
NZ592339A (en)	2012-09-28
IS8114A (is)	2005-11-01
RU2010147000A (ru)	2012-08-10
EP2319502A1 (en)	2011-05-11
CN101797241A (zh)	2010-08-11
AU2004228929A1 (en)	2004-10-21
DE202004021680U1 (de)	2010-04-22
NO20100250L (no)	2006-01-09
EP2316431B1 (en)	2015-09-30
WO2004089341A1 (en)	2004-10-21
JP2011006461A (ja)	2011-01-13
DE122011100047I1 (de)	2011-12-15
HRP20100601A2 (hr)	2011-03-31
TNSN05256A1 (en)	2007-07-10
US20110105620A1 (en)	2011-05-05
EP2008650A2 (en)	2008-12-31
EP2008650A3 (en)	2011-04-27
BRPI0409250A (pt)	2006-03-28
IS8885A (is)	2010-02-25
IL242037A0 (en)	2015-11-30
BRPI0409250B1 (pt)	2017-07-11
US20140255497A1 (en)	2014-09-11
US20060275357A1 (en)	2006-12-07
GR20040100121A (el)	2004-12-17
EP1613288A1 (en)	2006-01-11
PE20150676A1 (es)	2015-05-17
CN101797241B (zh)	2013-03-27
EP2316431A1 (en)	2011-05-04
HK1071685A1 (en)	2005-07-29
BE2011C030I2 (pl)	2023-03-07
CY2011013I2 (el)	2014-04-09
US20220031609A1 (en)	2022-02-03
RU2358716C2 (ru)	2009-06-20
NO20131287L (no)	2006-01-09
BE1015972A5 (fr)	2005-12-06
CL2011000450A1 (es)	2011-11-25
HRP20100600A2 (hr)	2011-03-31
NZ542622A (en)	2009-01-31
RU2012148593A (ru)	2014-05-20
AT501681A1 (de)	2006-10-15
BRPI0409250B8 (pt)	2022-01-18
IL170888A (en)	2010-06-16
IS2682B (is)	2010-10-15
AR043987A1 (es)	2005-08-17
HUE028247T2 (en)	2016-12-28
DK2316431T3 (en)	2016-01-11
NO2011016I1 (no)	2011-09-19
IL197578A0 (en)	2011-07-31
ES2320767T3 (es)	2009-05-28
PE20130200A1 (es)	2013-03-09
NO20055231D0 (no)	2005-11-07
JP2013177404A (ja)	2013-09-09
MY141249A (en)	2010-03-31
HRP20050886A2 (en)	2006-11-30
ES2228282A1 (es)	2005-04-01
IL197578A (en)	2015-10-29
US20190175527A1 (en)	2019-06-13
CY2011013I1 (el)	2014-04-09
HUS1100016I1 (hu)	2016-08-29
US8324283B2 (en)	2012-12-04
DK1613288T3 (da)	2009-03-23
JP5543298B2 (ja)	2014-07-09
CA2521325A1 (en)	2004-10-21
FR2854073A1 (fr)	2004-10-29
MA27729A1 (fr)	2006-01-02
ES2228282B1 (es)	2006-02-16
TWI332847B (en)	2010-11-11
HRP20100601B1 (hr)	2016-12-02
FR11C0036I1 (fr)	2011-10-14
CN1767819B (zh)	2010-07-28
LU91867I2 (fr)	2011-11-08
RU2475236C2 (ru)	2013-02-20
CY1110260T1 (el)	2014-04-09
KR101367574B1 (ko)	2014-02-25
CA2707750A1 (en)	2004-10-21
KR20110005320A (ko)	2011-01-17
US20200237690A1 (en)	2020-07-30
CL2004000745A1 (es)	2005-02-11
ZA200507394B (en)	2007-03-28
RU2010146697A (ru)	2012-05-27
SG175449A1 (en)	2011-11-28
US20130108675A1 (en)	2013-05-02
MXPA05010860A (es)	2006-05-25
RU2005134173A (ru)	2006-09-10
US20170290787A1 (en)	2017-10-12
GB2400318A (en)	2004-10-13
SI2316431T1 (sl)	2016-04-29
PE20050396A1 (es)	2005-07-05
KR20120101148A (ko)	2012-09-12
IE20040246A1 (en)	2004-12-15
RU2475237C2 (ru)	2013-02-20
ECSP056090A (es)	2006-03-01
HK1091114A1 (en)	2007-01-12
AT501681B1 (de)	2012-04-15
EP1613288B1 (en)	2008-11-19
FR2854073B1 (fr)	2008-03-14
JP5495467B2 (ja)	2014-05-21
AR078781A2 (es)	2011-11-30
ATE414508T1 (de)	2008-12-15
US20090203798A1 (en)	2009-08-13
LU91867I9 (pl)	2019-01-03
JP2004307506A (ja)	2004-11-04
CA2521325C (en)	2010-09-14
SI1613288T1 (sl)	2009-04-30
RU2009105403A (ru)	2010-08-27
AT504853A2 (de)	2008-08-15
TW200503784A (en)	2005-02-01
DE602004017847D1 (de)	2009-01-02
PE20090743A1 (es)	2009-07-17
NO335120B1 (no)	2014-09-22
NO20055231L (no)	2006-01-09
CN1767819A (zh)	2006-05-03
PL1613288T3 (pl)	2009-07-31
GR1005052B (el)	2005-11-30
EP2769713A1 (en)	2014-08-27
NO334116B1 (no)	2013-12-16
PE20131352A1 (es)	2013-11-14
AR078782A2 (es)	2011-11-30
CY1117071T1 (el)	2017-04-05
NO329332B1 (no)	2010-09-27
HRP20050886B1 (en)	2011-01-31
HK1155647A1 (en)	2012-05-25
FR11C0036I2 (fr)	2023-12-29
PT1613288E (pt)	2009-02-25
KR20050121712A (ko)	2005-12-27
US20080311188A1 (en)	2008-12-18
DE102004016947A1 (de)	2004-10-21
GB0407819D0 (en)	2004-05-12
AU2004228929B2 (en)	2008-02-07
NO2011016I2 (no)	2012-08-27

Publication	Publication Date	Title
HK1155647A1 (en)	2012-05-25	Solid oral composition comprising a s1p receptor agonist and a sugar alcohol s1p
PT2277521E (pt)	2015-07-01	Formulações orais de agonistas de opióides resistentes a adulteração
IL169902A0 (en)	2007-07-04	Sugar-free oral transmucosal solid dosage forms and uses thereof
HK1107768A1 (en)	2008-04-18	Solid drug for oral use
EP1701691A4 (en)	2009-11-04	METHODS AND COMPOSITIONS FOR ORAL HYGIENE
ZA200606174B (en)	2008-10-29	Multiparticulate formulations for oral delivery
HK1107012A1 (en)	2008-03-28	Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
ZA200508733B (en)	2006-09-27	Muscarinic M1 receptor agonists for pain management
IL177826A0 (en)	2006-12-31	Oral matrix formulations comprising licarbazepine
GB2391809B (en)	2006-01-11	Pharmaceutical composition comprising honey
EP1757273A4 (en)	2011-02-09	PREPARATION FOR ORAL ADMINISTRATION
IL161997A (en)	2005-12-18	Pharmaceutical composition comprising a 5ht1 receptor agonist
IL178296A0 (en)	2007-02-11	Pharmaceutical compositions containing a gaba?? receptor agonist
AU2003252683A8 (en)	2004-04-08	Composition for oral use
EP1811967A4 (en)	2008-08-20	METHOD AND FORMULATIONS FOR PREPARING PHARMACEUTICAL COMPOSITIONS WITH BUPROPION
EP1755477A4 (en)	2010-02-24	MOUTH HYGIENE COMPOSITIONS AND METHOD OF USE THEREOF
GB2403407B (en)	2006-12-13	Palatable oral anthelmintic composition
PL377147A1 (pl)	2006-01-23	Doustna kompozycja
AU2003280065A1 (en)	2004-06-15	Bupropion hydrochloride solid dosage forms
PL373776A1 (pl)	2005-10-03	Doustna kompozycja farmaceutyczna
GB0406393D0 (en)	2004-04-21	Oral composition
GB0406392D0 (en)	2004-04-21	Oral composition
GB0413138D0 (en)	2004-07-14	Preparation for oral administration
AU2004900654A0 (en)	2004-02-26	Oral Hygiene Device